Other
Neoplasm by Special Category
CI-CAN-00000004Explore in graph →
Non-malignant21,340 active trials259 approved drugs3,859 evidence items
- NCIt
- C7062
Loading cancer entity…
Loading cancer entity…
Other
CI-CAN-00000004Explore in graph →
Clinical trials
95,701 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04946864 | A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer | suspended | Phase 1 / Phase 2 | 65 | Ascentage Pharma Group Inc.INDUSTRY | 2 | Aug 19, 2024 | clinicaltrials |
| NCT03181035 | Correlation of FAZA PET Hypoxia Imaging To 3D Histology in Oral Tongue Cancer(FAITH) | suspended | Phase 1 / Phase 2 | 10 | Sunnybrook Health Sciences CentreOTHER | 1 | Aug 12, 2024 |
| clinicaltrials |
| NCT04120246 | Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer | suspended | Phase 1 | 24 | Veana TherapeuticsINDUSTRY | 1 | Jul 10, 2024 | clinicaltrials |
| NCT04714983 | DNX-2440 for Resectable Colorectal Liver Metastasis | suspended | Phase 1 | 30 | DNAtrix, Inc.INDUSTRY | 1 | Apr 9, 2024 | clinicaltrials |
| NCT03932253 | MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b) | suspended | Phase 1 | 79 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.INDUSTRY | 1 | Mar 27, 2024 | clinicaltrials |
| NCT05101616 | A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer | suspended | Phase 1 / Phase 2 | 100 | Shanghai Minimally Invasive Surgery CenterOTHER | 1 | Mar 7, 2024 | clinicaltrials |
| NCT02579005 | Radio-Immuno-Modulation in Lung Cancer(RIM) | suspended | Phase 1 | 24 | Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de MontrealOTHER | 1 | Feb 29, 2024 | clinicaltrials |
| NCT05168904 | A Study to Investigate Fadraciclib (CYC065), in Subjects With Leukemia or Myelodysplastic Syndrome (MDS) | suspended | Phase 1 / Phase 2 | 210 | Cyclacel Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 8, 2024 | clinicaltrials |
| NCT04996030 | A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia | suspended | Phase 1 | 16 | Syros PharmaceuticalsINDUSTRY | 1 | Jan 23, 2024 | clinicaltrials |
| NCT04505813 | Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma | suspended | Phase 1 / Phase 2 | 9 | NexImmune Inc.INDUSTRY | 1 | Jan 16, 2024 | clinicaltrials |
| NCT04558684 | Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer | suspended | Phase 1 / Phase 2 | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Jan 3, 2024 | clinicaltrials |
| NCT05425862 | Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate Cancer(REPAIR) | suspended | Phase 1 | 48 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Dec 11, 2023 | clinicaltrials |
| NCT04828174 | Anti-TRBC1 CAR-T Cell Therapy in Patients With TRBC1 Positive T Cell Malignancies | suspended | Phase 1 | 9 | Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 29, 2023 | clinicaltrials |
| NCT05138458 | A Study of MT-101 in Subjects With CD5+ Relapsed/Refractory TCL(IMAGINE) | suspended | Phase 1 / Phase 2 | 40 | Myeloid TherapeuticsINDUSTRY | 1 | Nov 13, 2023 | clinicaltrials |
| NCT04485052 | Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia | suspended | Phase 1 / Phase 2 | 222 | Innovent Biologics (Suzhou) Co. Ltd.INDUSTRY | 1 | Oct 23, 2023 | clinicaltrials |
| NCT03859752 | TR1801-ADC in Patients With Tumors That Express c-Met | suspended | Phase 1 | 15 | Open Innovation Partners, Inc.INDUSTRY | 1 | Sep 22, 2023 | clinicaltrials |
| NCT04650451 | Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors | suspended | Phase 1 | 220 | Bellicum PharmaceuticalsINDUSTRY | 1 | Apr 20, 2023 | clinicaltrials |
| NCT01933815 | Dose-Escalation Study of TPI 287 + Avastin Followed by Randomized Study of the Same Versus Avastin for Glioblastoma | suspended | Phase 1 / Phase 2 | 92 | Cortice Biosciences, Inc.INDUSTRY | 1 | Feb 22, 2023 | clinicaltrials |
| NCT04042116 | A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor | suspended | Phase 1 / Phase 2 | 227 | Clovis Oncology, Inc.INDUSTRY | 6 | Dec 20, 2022 | clinicaltrials |
| NCT04746131 | Safety and Pharmacokinetic Study of IMM0306 in Patients With Refractory or Relapsed CD20-positive B-cell Non-Hodgkin's Lymphoma (B-NHL) | suspended | Phase 1 | 90 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc.OTHER | 1 | Sep 26, 2022 | clinicaltrials |
| NCT03970382 | A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors | suspended | Phase 1 | 21 | PACT Pharma, Inc.INDUSTRY | 1 | Aug 18, 2022 | clinicaltrials |
| NCT03704714 | Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma | suspended | Phase 1 / Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Aug 15, 2022 | clinicaltrials |
| NCT04506983 | GPC3-CAR-T Cells for the Hepatocellular Carcinoma | suspended | Phase 1 | 12 | Beijing Tsinghua Chang Gung HospitalOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT02910752 | CLAM Chemotherapy With PBSC Support for Relapsed Patients After Allogeneic Stem Cell Transplantation | suspended | Phase 1 / Phase 2 | 20 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Nov 26, 2021 | clinicaltrials |
| NCT01562626 | Phase I/II Study of APS001F With Flucytosine and Maltose in Solid Tumors | suspended | Phase 1 / Phase 2 | 75 | Anaeropharma Science, Inc.INDUSTRY | 1 | May 12, 2021 | clinicaltrials |
| NCT03722186 | Safety, Tolerability and Pharmacokinetics/Pharmacodynamics (PK/PD) of SHR-1603 in Subjects With Advanced Malignancies | suspended | Phase 1 | 128 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Mar 22, 2021 | clinicaltrials |
| NCT03120130 | Study of Amblyomin-X in Advanced Solid Tumor(Amblyomin-X) | suspended | Phase 1 | 24 | União Química Farmacêutica Nacional S/AINDUSTRY | 1 | Oct 14, 2019 | clinicaltrials |
| NCT01974479 | Pilot Study of Redirected Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia | suspended | Phase 1 | 20 | National University Health System, SingaporeOTHER | 1 | Apr 12, 2019 | clinicaltrials |
| NCT01627795 | Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment | suspended | Phase 1 / Phase 2 | 17 | Oshadi Drug AdministrationINDUSTRY | 1 | Apr 18, 2018 | clinicaltrials |
| NCT02026362 | Multiple Antigen Specific Cell Therapy (MASCT) for Hepatocellular Carcinoma(HCC) Patients After Radical Resection or Radio Frequency Ablation(RFA).(HCC DC CTL) | suspended | Phase 1 / Phase 2 | 100 | HRYZ Biotech Co.INDUSTRY | 1 | Oct 18, 2017 | clinicaltrials |
| NCT02093871 | A Phase 1 Trial of Perfusion Induced Systemic Hyperthermia (PISH) Over Multiple Cycles for Terminal Ovarian Cancer(PISH-2) | suspended | Phase 1 | 20 | ThermalCore IncINDUSTRY | 1 | Jul 21, 2017 | clinicaltrials |
| NCT00664196 | Trial of Anti-PSMA Designer T Cells in Advanced Prostate Cancer After Non-Myeloablative Conditioning | suspended | Phase 1 | 18 | Roger Williams Medical CenterOTHER | 1 | Jun 17, 2016 | clinicaltrials |
| NCT00673829 | Trial of 2nd Generation Anti-CEA Designer T Cells in Metastatic Breast Cancer | suspended | Phase 1 | 26 | Roger Williams Medical CenterOTHER | 1 | Jun 17, 2016 | clinicaltrials |
| NCT01211691 | Study of KB004 in Subjects With Hematologic Malignancies (Myelodysplastic Syndrome, MDS, Myelofibrosis, MF) | suspended | Phase 1 / Phase 2 | 120 | Humanigen, Inc.INDUSTRY | 2 | Nov 17, 2015 | clinicaltrials |
| NCT00624182 | Gemcitabine With Peptide Vaccine Therapy in Treating Patients With Bile Duct Cancer | suspended | Phase 1 | 9 | Akita University HospitalOTHER | 1 | Jun 23, 2015 | clinicaltrials |
| NCT01762410 | Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors | suspended | Phase 1 | 60 | Piramal Enterprises LimitedINDUSTRY | 2 | Sep 29, 2014 | clinicaltrials |
| NCT01779336 | Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors | suspended | Phase 1 | 70 | Piramal Enterprises LimitedINDUSTRY | 2 | Sep 29, 2014 | clinicaltrials |
| NCT01841463 | Study of an Oral Cdk Inhibitor Administered With an Oral BRAF Inhibitor in Patients With Advanced or Inoperable Malignant Melanoma With BRAF Mutation | suspended | Phase 1 | 100 | Piramal Enterprises LimitedINDUSTRY | 1 | Sep 4, 2014 | clinicaltrials |
| NCT02117336 | Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) | suspended | Phase 1 | 36 | Piramal Enterprises LimitedINDUSTRY | 1 | Sep 3, 2014 | clinicaltrials |
| NCT01604863 | A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies | suspended | Phase 1 | 54 | Human Genome Sciences Inc., a GSK CompanyINDUSTRY | 1 | Nov 1, 2012 | clinicaltrials |
| NCT00003980 | BIBX 1382 in Treating Patients With Solid Tumors | suspended | Phase 1 | 80 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 9 | Jul 11, 2012 | clinicaltrials |
| NCT01226056 | Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets | suspended | Phase 1 / Phase 2 | 45 | Southern Europe New Drug OrganizationOTHER | 1 | Oct 21, 2010 | clinicaltrials |
| NCT00209729 | Phase I/II Study of Oral S-1 Plus Docetaxel in Elderly Patients With Advanced Gastric Cancer. | suspended | Phase 1 / Phase 2 | 50 | Hokkaido Gastrointestinal Cancer Study GroupOTHER | 1 | May 26, 2010 | clinicaltrials |
| NCT00909558 | Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer | suspended | Phase 1 | 24 | Envita Medical Center, Inc.INDUSTRY | 1 | Feb 24, 2010 | clinicaltrials |
| NCT00459823 | A Dose Escalation Study of E7107 Administered IV (Bolus) on Days 1, 8, and 15 Every 28 Days to Patients With Solid Tumours | suspended | Phase 1 | 40 | Eisai LimitedINDUSTRY | 2 | Mar 24, 2009 | clinicaltrials |
| NCT00827203 | A Safety Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium in Patients With Solid Tumors | suspended | Phase 1 | 30 | Synta Pharmaceuticals Corp.INDUSTRY | 1 | Mar 9, 2009 | clinicaltrials |
| NCT00499499 | A Dose Escalation Study of E7107 Administered Intravenously on Days 1 and 8 Every 21 Days to Patients With Solid Tumors | suspended | Phase 1 | 40 | Eisai Inc.INDUSTRY | 1 | Feb 4, 2009 | clinicaltrials |
| NCT00637364 | High Intensity Focused Ultrasound Tumor Treatment for Pancreatic Cancer Pain(HIFU Pancreas) | suspended | Phase 1 / Phase 2 | 5 | CMED HIFU Development CorporationINDUSTRY | 1 | Jan 13, 2009 | clinicaltrials |
| NCT00753480 | A Study of D4064A Administered to Patients With Recurrent or Persistent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | suspended | Phase 1 | 56 | Genentech, Inc.INDUSTRY | 1 | Nov 7, 2008 | clinicaltrials |
| NCT00460278 | Study of XL418 in Adults With Solid Tumors | suspended | Phase 1 | 63 | ExelixisINDUSTRY | 1 | Jun 4, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Aug 19, 2024source: clinicaltrials